The priority review voucher: a misconceived quid pro quo.
作者信息
Olliaro Piero, Torreele Els
机构信息
ISARIC, Pandemic Sciences Institute, Nufflield Departmente of Medicine, University of Oxford, Oxford, UK
Independent Researcher, Geneva, Switzerland.
出版信息
BMJ Glob Health. 2024 Dec 3;9(12):e015933. doi: 10.1136/bmjgh-2024-015933.
Abstract
摘要
相似文献
1
The priority review voucher: a misconceived quid pro quo.优先审评券：一种被误解的交换条件。
BMJ Glob Health. 2024 Dec 3;9(12):e015933. doi: 10.1136/bmjgh-2024-015933.
2
Quid pro quo revisited: the basis of marital therapy.重温交换条件：婚姻治疗的基础。
Am J Orthopsychiatry. 1986 Jul;56(3):371-384. doi: 10.1111/j.1939-0025.1986.tb03470.x.
3
From quid pro quo to quid pro bono: reshaping the influence of industry on health care epidemiologists.从有代价的交换到无偿服务：重塑行业对医疗保健流行病学家的影响。
Clin Infect Dis. 2010 Jan 1;50(1):93-7. doi: 10.1086/648723.
4
The cost-effectiveness of a competitive voucher scheme to reduce sexually transmitted infections in high-risk groups in Nicaragua.尼加拉瓜一项竞争性代金券计划在高危人群中减少性传播感染的成本效益。
Health Policy Plan. 2005 Jul;20(4):222-31. doi: 10.1093/heapol/czi026.
5
Financial management. Quid pro quo.财务管理。交换条件。
Health Serv J. 1993 Nov 25;103(5380):36-7.
6
Quid pro quo and the pharmascolds.交换条件与药品批评者。
Nat Rev Gastroenterol Hepatol. 2009 Aug;6(8):437. doi: 10.1038/nrgastro.2009.129.
7
The Quid Pro Quo.交换条件。
Ind Med Gaz. 1869 May 1;4(5):102.
8
ONR London: Two Decades of Scientific Quid pro Quo.美国海军研究办公室伦敦分部：二十年的科学交换条件。
Science. 1966 Nov 4;154(3749):623-5. doi: 10.1126/science.154.3749.623.
9
No coincidence, just quid pro quo.没有巧合，只有交换条件。
Am J Nurs. 1994 Oct;94(10):7.
10
Quid pro quo! How to work together and keep Nurse Practice Act current.有来有往！如何共同努力并使《护士执业法》与时俱进。
Ariz Nurse. 1976 Nov-Dec;29(5):7-9.
引用本文的文献
1
Cholera vaccines for the rich, cholera for the poor: While the global cholera vaccine stockpile runs dry, a booming market for high-income countries exemplifies the chasm between commercial interests and global health needs.霍乱疫苗供富人，霍乱留给穷人：在全球霍乱疫苗储备告罄之际，高收入国家蓬勃发展的市场凸显了商业利益与全球卫生需求之间的鸿沟。
PLOS Glob Public Health. 2025 Mar 24;5(3):e0004359. doi: 10.1371/journal.pgph.0004359. eCollection 2025.
本文引用的文献
1
Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis: a commentary on the proposed EU pharma regulation.可转让数据独占性凭证并非解决抗菌药物研发危机的办法：对欧盟拟议药品法规的评论
BMJ Glob Health. 2024 Feb 28;9(2):e014605. doi: 10.1136/bmjgh-2023-014605.
2
European priority review vouchers for neglected disease product development.欧洲优先审评券，用于治疗被忽视疾病的药物研发。
BMJ Glob Health. 2024 Jan 30;9(1):e013686. doi: 10.1136/bmjgh-2023-013686.
3
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.药物研发的特殊 FDA 认定：孤儿药、快速通道、加速批准、优先审评和突破性疗法。
Eur J Health Econ. 2024 Aug;25(6):979-997. doi: 10.1007/s10198-023-01639-x. Epub 2023 Nov 14.
4
From private incentives to public health need: rethinking research and development for pandemic preparedness.从私人激励到公共卫生需求：重新思考大流行防范的研发工作。
Lancet Glob Health. 2023 Oct;11(10):e1658-e1666. doi: 10.1016/S2214-109X(23)00328-5. Epub 2023 Aug 28.
5
Breakthrough treatments for Ebola virus disease, but no access-what went wrong, and how can we do better?埃博拉病毒病的突破性疗法，但无法获得——出了什么问题，我们如何才能做得更好？
Lancet Infect Dis. 2023 Jul;23(7):e253-e258. doi: 10.1016/S1473-3099(22)00810-6. Epub 2023 Jan 19.
6
The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases.优先审评券对热带病研究与开发的影响。
Pharmaceut Med. 2022 Jun;36(3):189-197. doi: 10.1007/s40290-022-00427-x. Epub 2022 May 19.
7
European governments should align medicines pricing practices with global transparency norms and legal principles.欧洲各国政府应使药品定价做法符合全球透明度规范和法律原则。
Lancet Reg Health Eur. 2022 Apr 21;16:100375. doi: 10.1016/j.lanepe.2022.100375. eCollection 2022 May.
8
Reboot biomedical R&D in the global public interest.为了全球公共利益重启生物医学研发。
Nature. 2022 Feb;602(7896):207-210. doi: 10.1038/d41586-022-00324-y.
9
Priority Review Vouchers: GAO Report Provides Scant Evidence of Success.优先审评券：政府问责局的报告几乎没有提供成功的证据。
Clin Transl Sci. 2021 Jan;14(1):8-10. doi: 10.1111/cts.12878. Epub 2020 Sep 19.
10
Public investments in the clinical development of bedaquiline.对贝达喹啉临床开发的公共投资。
PLoS One. 2020 Sep 18;15(9):e0239118. doi: 10.1371/journal.pone.0239118. eCollection 2020.
Zotero 插件